Discovery of Cancer Stem Cell Biomarkers Using Metabolomics [ASMS 2010]
Stemina Biomarker Discovery, Inc. has engaged in a study to discover metabolomic biomarkers that are potential indicators of drug efficacy against cancer stem cells (CSCs) for the establishment of novel drug screening assays. The primary cellular target used in this screen was cancer stem cells derived from glioblastoma multiforme (GBM), brain tumor stem cells (BTSCs), as well as non-cancer stem cells derived from the same tumors. BTSCs have successfully been isolated and are believed to be the cause of tumor recurrence. Further, GBM is one of the most malignant forms of cancer and despite extensive efforts for therapeutic intervention, the mean survival time following diagnosis has remained at one year. This fact highlights the eminent, and urgent need to discover novel drugs that are specific to this form of malignant gliomas.